Bio-Rad Laboratories, Inc.

NYSE:BIO

Medical - Devices

Healthcare
$370.17 -0.23%

-$0.65 today

Market cap
$9.95B
Beta
1.08
P/E (TTM)
45.4
EPS (TTM)
$6.26
52W Low $228.40High $343.12

Volume 0.46M

Average 0.38M

BIO Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Bio-Rad Laboratories, Inc.NYSE: BIO

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin widens to 57.1%

Net margin was 57.1% in Q2 FY2026, up 8.3 pp from a year earlier. On a trailing-twelve-month basis it was 8.6%, down 3.9 pp year over year. Over 3 fiscal years it widened by 158.9 pp.

Context

  • Net margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 2 analysts of 10.5% for the fiscal year ending Dec 2026, down from 29.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
57.1%+146.1 pp QoQ
Last fiscal yearDec 2025
29.4%+101.3 pp YoY
LTMJun 2026
8.6%-3.9 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+8.3 pp+61.6 pp+53.3 pp
1 year+101.3 pp-18.9 pp-120.2 pp
3 years+158.9 pp-17.6 pp-176.4 pp
5 years-15.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
29.4%
Year-over-year change
+101.3pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How BIO compares with its peers on the latest reported figures

  • BIO's LTM Jun 2026 net margin of 8.6% is the 4th highest of the 11 companies compared; the peer median is 1.6%.
  • Its year-over-year change of -3.9 pp is the 8th highest of 11, against a peer median of +1.2 pp.
  • Over three fiscal years its change of +158.9 pp compares with a peer median of -12.2 pp.
BIO Competitors Peer median
Net Margin for BIO and competitors
Company Period LTM level YoY 3-year change
DHRDanaher CorporationLTM Sep 202616.9% +2.5 pp-12.3 pp
TMOThermo Fisher Scientific Inc.LTM Sep 202615.0% -0.1 pp-0.4 pp
TECHBio-Techne CorporationLTM Sep 202614.0% +7.6 pp-10.1 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 20268.6% -3.9 pp+158.9 pp
RVTYRevvity, Inc.LTM Jul 20268.2% -2.1 pp-8.7 pp
RGENRepligen CorporationLTM Jun 20265.3% +7.3 pp-16.6 pp
BRKRBruker CorporationLTM Jun 2026-2.0% -4.3 pp-12.0 pp
AZTAAzenta, Inc.LTM Sep 2026-26.9% -17.9 pp-24.7 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-37.1% +53.1 pp-95.3 pp
PACBPacific Biosciences of California, Inc.LTM Mar 2026-80.3% +351.4 pp-96.5 pp
LABStandard BioTools Inc.LTM Mar 2026-109.1% -10.3 pp+106.3 pp
Peer median (excluding BIO) 1.6%+1.2 pp-12.2 pp

Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.92B2.8B2.67B2.57B2.58B
Cost of Revenue1.28B1.23B1.24B1.19B1.24B
Gross Profit1.64B1.57B1.43B1.38B1.34B
Gross Margin56.1%55.9%53.4%53.7%52.0%
Research & Development260.64M256.89M247.43M295.9M256.9M
Selling, General & Admin877.12M827.83M841.7M814M819.9M
Operating Expenses1.14B1.08B1.09B1.11B1.08B
Depreciation & Amortization137.6M137.3M145.9M151.6M165.4M
EBITDA5.59B(4.53B)(654.8M)(2.14B)1.21B
EBITDA Margin191.2%-161.6%-24.5%-83.5%46.8%
Operating Income500.34M482.62M337.8M269M270.5M
Operating Margin17.1%17.2%12.6%10.5%10.5%
Interest Income18.9M58M100.9M82M95.5M
Interest Expense1.55M38.11M49.44M48.9M49M
Other Income / Expenses4.95B(5.19B)(1.19B)(2.61B)725M
Income Before Tax5.45B(4.7B)(850.1M)(2.34B)995.5M
Pre-Tax Margin186.4%-167.9%-31.8%-91.3%38.5%
Income Tax Expense1.19B(1.08B)(212.78M)(498.3M)235.6M
Net Income4.25B(3.63B)(637.32M)(1.84B)759.9M
Net Margin145.6%-129.5%-23.9%-71.9%29.4%
EPS (Basic)142.61(121.79)(21.82)(65.36)27.87
EPS (Diluted)140.83(121.79)(21.82)(65.36)27.87
Weighted Avg Shares29.83M29.79M29.21M28.21M27.26M
Weighted Avg Shares (Diluted)30.21M29.79M29.21M28.21M27.28M

Bio-Rad Laboratories, Inc.

NYSE:BIO

Intrinsic Alpha fair value

Locked

Current Price

$370.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.